PDCD1 and Hodgkins lymphoma: The use of anti-programmed cell death protein-1 (PD-1) has shown remarkable efficacy in tumors, especially in r/r classic Hodgkin lymphoma, with an objective response rate (ORR) of approximately 70% (10).